{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:59:22Z","timestamp":1780981162207,"version":"3.54.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Refractory cancer pain remains difficult to control in older adults, particularly when oral opioid regimens are limited by dysphagia, nausea, bowel dysfunction, or rapidly fluctuating symptom intensity. In this retrospective real-world study conducted in a dedicated geriatric oncology ward, subcutaneous patient-controlled analgesia (PCA) with hydromorphone was evaluated as a routinely implemented rescue strategy for severe opioid-refractory cancer pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the effectiveness and safety of subcutaneous PCA hydromorphone for refractory cancer pain in hospitalized older patients and to identify clinical factors associated with 24-h pain reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed consecutive admissions from January 1 to December 31, 2024. Eligible patients were aged \u226560 years, had pathologically confirmed malignancy, had refractory cancer pain defined as a pre-PCA current NRS score \u22654 recorded within 30 min before pump initiation after prior opioid exposure, and received subcutaneous hydromorphone PCA with at least one follow-up pain assessment. The primary endpoint was change in current NRS score from immediately pre-PCA to 24 h. Secondary endpoints included early analgesic response, responder rates, dosing patterns, and documented adverse events. Complete-case analyses were pre-specified; sensitivity analyses excluded implausible physiologic values and refitted the multivariable model with robust standard errors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 499 patients (mean age 68.3 \u00b1 6.9 years; 69% male), 82% had stage IV disease. Mean pre-PCA current NRS decreased from 4.43 \u00b1 1.29 to 2.21 \u00b1 0.73 at 24 h, corresponding to a mean reduction of 2.18 points (95% CI 2.05\u20132.31;\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001), a magnitude generally regarded as clinically meaningful for severe cancer pain. Response rates at 24 h were 57.3% for \u226530% improvement and 45.2% for \u226550% improvement. Median time to satisfactory analgesia was 0.6 h. Adverse events were ascertained from standardized nursing assessments embedded in routine charting and verified against medication and progress-note documentation; somnolence occurred in 2\/499 patients (0.4%) and constipation in 1\/499 (0.2%), with no documented respiratory depression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In a specialized geriatric oncology ward, subcutaneous PCA hydromorphone was associated with rapid and clinically meaningful short-term pain improvement and a low rate of documented adverse events. These findings support its use as a pragmatic rescue option for carefully selected older patients with refractory cancer pain, while prospective comparative studies remain necessary before broad implementation can be recommended.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1731569","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:31:04Z","timestamp":1780979464000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Subcutaneous patient-controlled analgesia with hydromorphone for the treatment of refractory cancer pain in older hospitalized patients: a retrospective real-world study"],"prefix":"10.3389","volume":"13","author":[{"given":"Hong","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Geriatric Oncology, Chongqing University Cancer Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Shen","sequence":"additional","affiliation":[{"name":"Emergency Department, Chongqing Emergency Medical Center, Chongqing University Central Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Chen","sequence":"additional","affiliation":[{"name":"Nutritional Department, Chongqing University Cancer Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Geriatric Oncology, Chongqing University Cancer Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Geriatric Oncology, Chongqing University Cancer Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqing","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Geriatric Oncology, Chongqing University Cancer Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1053\/j.seminoncol.2003.12.024","article-title":"Cancer in older persons: an international issue in an aging world","volume":"31","author":"Yancik","year":"2004","journal-title":"Semin Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","article-title":"Update on prevalence of pain in patients with cancer: systematic review and meta-analysis","volume":"51","author":"van den Beuken-van Everdingen","year":"2016","journal-title":"J Pain Symptom Manag"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1200\/JCO.2014.57.4822","article-title":"Geriatric oncology: an overview","volume":"32","author":"Lichtman","year":"2014","journal-title":"J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"iv166","DOI":"10.1093\/annonc\/mdy152","article-title":"Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines","volume":"29","author":"Fallon","year":"2018","journal-title":"Ann Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1200\/JCO.2013.52.5188","article-title":"Principles of opioid use in cancer pain","volume":"32","author":"Portenoy","year":"2014","journal-title":"J Clin Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/00130404-201707000-00009","article-title":"Managing cancer pain in older adults","volume":"23","author":"Guerard","year":"2017","journal-title":"Cancer J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.critrevonc.2015.12.011","article-title":"Opioid switching in cancer pain: from the beginning to nowadays","volume":"99","author":"Mercadante","year":"2016","journal-title":"Crit Rev Oncol Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1345\/aph.1D395","article-title":"Continuous subcutaneous infusion of opiates at end-of-life","volume":"38","author":"Anderson","year":"2004","journal-title":"Ann Pharmacother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/0140-6736(91)93401-T","article-title":"Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain","volume":"337","author":"Moulin","year":"1991","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003348.pub3","article-title":"Patient controlled analgesia versus non-patient controlled analgesia for acute pain","author":"McNicol","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.6004\/jnccn.2020.7699","article-title":"Comparing patient-controlled analgesia versus non-PCA hydromorphone titration for severe cancer pain: a randomized phase III trial","volume":"19","author":"Lin","year":"2021","journal-title":"J Natl Compr Canc Netw."},{"key":"B12","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.jpainsymman.2005.01.007","article-title":"Hydromorphone","volume":"29","author":"Murray","year":"2005","journal-title":"J Pain Symptom Manage."},{"key":"B13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0304-3959(97)00018-3","article-title":"Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study","volume":"72","author":"Lawlor","year":"1997","journal-title":"Pain."},{"key":"B14","first-page":"179","article-title":"Pain management in the elderly population: a review","volume":"10","author":"Kaye","year":"2010","journal-title":"Ochsner J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0304-3959(93)90051-P","article-title":"Comparison of hydromorphone continuous subcutaneous infusion and basal rate subcutaneous infusion plus PCA in cancer pain: a pilot study","volume":"53","author":"Vanier","year":"1993","journal-title":"Pain."},{"key":"B16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jpainsymman.2023.09.018","article-title":"Patient-controlled subcutaneous analgesia of hydromorphone versus morphine to treat moderate and severe cancer pain: a randomized double-blind controlled trial","volume":"67","author":"Zeng","year":"2024","journal-title":"J Pain Symptom Manage."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von","year":"2007","journal-title":"Lancet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0140-6736(74)91639-0","article-title":"Assessment of coma and impaired consciousness: a practical scale","volume":"2","author":"Teasdale","year":"1974","journal-title":"Lancet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain."},{"key":"B21","first-page":"891","article-title":"Subcutaneous narcotic infusions for cancer pain: treatment outcome and guidelines for use","volume":"146","author":"Moulin","year":"1992","journal-title":"CMAJ."},{"key":"B22","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1089\/jpm.2005.8.743","article-title":"Intravenous versus subcutaneous morphine titration in patients with persisting exacerbation of cancer pain","volume":"8","author":"Elsner","year":"2005","journal-title":"J Palliat Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41571-018-0143-7","article-title":"Balancing opioid analgesia with the risk of nonmedical opioid use in patients with cancer","volume":"16","author":"Arthur","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1016\/S1470-2045(18)30415-7","article-title":"Integration of oncology and palliative care: a Lancet Oncology Commission","volume":"19","author":"Kaasa","year":"2018","journal-title":"Lancet Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"161508","DOI":"10.1155\/2015\/161508","article-title":"Morphine promotes tumor angiogenesis and increases breast cancer progression","volume":"2015","author":"Bimonte","year":"2015","journal-title":"Biomed Res Int."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1731569\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:31:22Z","timestamp":1780979482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1731569\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":27,"alternative-id":["10.3389\/fmed.2026.1731569"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1731569","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"article-number":"1731569"}}